CADENCE PHARMACEUTICALS, INC COM STK
CADX
CADX was delisted on the 18th of March, 2014.
3 hedge funds and large institutions have $3.77M invested in CADENCE PHARMACEUTICALS, INC COM STK in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 98 closing their positions.
97% less funds holding
Funds holding: 100 → 3 (-97)
99% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 98
99% less capital invested
Capital invested by funds: $458M → $3.77M (-$454M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OP
Omni Partners
London,
United Kingdom
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$55.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$54.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$46.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$28.3M |
CADX Hedge Fund Activity: Q1 2014 in Review
3 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in CADENCE PHARMACEUTICALS, INC COM STK (CADX) for Q1 2014, worth a combined $3.77M — down 99% from $458M a quarter earlier.
Sellers outnumbered buyers: 98 funds closed out of CADX and 1 opened new positions — a net loss of 97 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Omni Partners, opening a new position worth an estimated $3.09M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $55.3M sold.
- 3 institutional investors held CADENCE PHARMACEUTICALS, INC COM STK (CADX) as of Q1 2014, down from 100 in Q4 2013.
- Funds reported $3.77M of CADENCE PHARMACEUTICALS, INC COM STK stock for Q1 2014, down 99% quarter-over-quarter.
- 1 fund opened new CADENCE PHARMACEUTICALS, INC COM STK positions in Q1 2014 and 98 closed out, a net change of -97 holders.
- The largest CADENCE PHARMACEUTICALS, INC COM STK buyer in Q1 2014 was Omni Partners, an estimated $3.09M added.
- The largest CADENCE PHARMACEUTICALS, INC COM STK seller in Q1 2014 was Capital Research Global Investors, an estimated $55.3M sold.
Based on aggregated 13F filings for Q1 2014.